Esophageal subepithelial lesion diagnosed as malignant gastrointestinal neuroectodermal tumor.
Kim SB, Lee SH, Gu MJ.
World J Gastroenterol. 2015 May 14;21(18):5739-43. doi: 10.3748/wjg.v21.i18.5739.
Prognostic biomarkers for immunotherapy in esophageal cancer.
Tong X, Jin M, Wang L, Zhang D, Yin Y, Shen Q.
Front Immunol. 2024 Sep 30;15:1420399. doi: 10.3389/fimmu.2024.1420399. eCollection 2024.
GPR37-enhanced ubiquitination of ATP1A1 inhibits tumor progression and radiation resistance in esophageal squamous cell carcinoma.
Hu J, Meng F, Lv L, Hong F, He Q, Zhu Q, Tian T, Chang N, Zhang S, Yi Q, Qian L.
Cell Death Dis. 2024 Dec 27;15(12):933. doi: 10.1038/s41419-024-07240-1.
Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
Hamai Y, Emi M, Ibuki Y, Kurokawa T, Yoshikawa T, Ohsawa M, Hirohata R, Kitasaki N, Okada M.
Anticancer Res. 2022 Dec;42(12):6037-6045. doi: 10.21873/anticanres.16115.
Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Tang H, Jiang D, Zhang S, Zeng Z, Tan L, Hou Y, Wang Q; Zhongshan NCRT-EC working group; Wang H, Zhu J, Shen Y, Yin J, Ge D.
J Thorac Cardiovasc Surg. 2021 Dec;162(6):1632-1641. doi: 10.1016/j.jtcvs.2020.09.042. Epub 2020 Sep 17.
High-grade malignant stricture is predictive of esophageal tumor stage. Risks of endosonographic evaluation.
Van Dam J, Rice TW, Catalano MF, Kirby T, Sivak MV Jr.
Cancer. 1993 May 15;71(10):2910-7. doi: 10.1002/1097-0142(19930515)71:10<2910::aid-cncr2820711005>3.0.co;2-l.
CircJPH1 regulates the NF-kappaB/HERC5 axis to promote the malignant progression of esophageal squamous cell carcinoma through binding to XRCC6.
Liu J, Wei Z, Meng L, Wu L, Liu F, Sang M, Zhao L, Gu L, Shan B.
Cell Signal. 2024 Dec;124:111403. doi: 10.1016/j.cellsig.2024.111403. Epub 2024 Sep 8.
Esophageal sarcomas.
Perch SJ, Soffen EM, Whittington R, Brooks JJ.
J Surg Oncol. 1991 Nov;48(3):194-8. doi: 10.1002/jso.2930480311.
A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.
Zhou Z, Zhang H, Du J, Yang J, Pan W, Zhang Q, Wang H, Tang P, Ba Y, Zhang H.
Cell Death Dis. 2024 Sep 10;15(9):663. doi: 10.1038/s41419-024-06986-y.
Malignant Esophageal Glomus Tumor With CARMN::NOTCH2 Fusion: An Additional Tumor Underscoring the Frequent Tendency of Esophageal Glomus Tumors for Aggressive Behavior.
Pancsa T, Martínek P, Michal M.
Int J Surg Pathol. 2025 Jun;33(4):987-991. doi: 10.1177/10668969241291887. Epub 2024 Nov 10.
